electroCore (ECOR) Competitors $4.82 -0.20 (-3.96%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ECOR vs. INO, LNSR, LAKE, BSGM, PDEX, PROF, RCEL, SPAI, OBIO, and NSPRShould you be buying electroCore stock or one of its competitors? The main competitors of electroCore include Inovio Pharmaceuticals (INO), LENSAR (LNSR), Lakeland Industries (LAKE), Biosig Technologies (BSGM), Pro-Dex (PDEX), Profound Medical (PROF), Avita Medical (RCEL), Safe Pro Group (SPAI), Orchestra BioMed (OBIO), and InspireMD (NSPR). These companies are all part of the "medical equipment" industry. electroCore vs. Its Competitors Inovio Pharmaceuticals LENSAR Lakeland Industries Biosig Technologies Pro-Dex Profound Medical Avita Medical Safe Pro Group Orchestra BioMed InspireMD electroCore (NASDAQ:ECOR) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Is ECOR or INO more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to electroCore's net margin of -47.84%. Inovio Pharmaceuticals' return on equity of -163.32% beat electroCore's return on equity.Company Net Margins Return on Equity Return on Assets electroCore-47.84% -221.93% -69.17% Inovio Pharmaceuticals N/A -163.32%-96.41% Which has more volatility & risk, ECOR or INO? electroCore has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ECOR or INO? 26.7% of electroCore shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 13.8% of electroCore shares are held by insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to ECOR or INO? In the previous week, electroCore and electroCore both had 3 articles in the media. electroCore's average media sentiment score of 0.84 beat Inovio Pharmaceuticals' score of 0.30 indicating that electroCore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment electroCore 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ECOR or INO? electroCore currently has a consensus target price of $25.50, suggesting a potential upside of 428.94%. Inovio Pharmaceuticals has a consensus target price of $8.80, suggesting a potential upside of 262.14%. Given electroCore's stronger consensus rating and higher probable upside, equities research analysts clearly believe electroCore is more favorable than Inovio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score electroCore 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Inovio Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation and earnings, ECOR or INO? electroCore has higher revenue and earnings than Inovio Pharmaceuticals. electroCore is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioelectroCore$25.18M1.45-$11.89M-$1.62-2.98Inovio Pharmaceuticals$182.34K708.24-$107.25M-$2.61-0.93 SummaryelectroCore beats Inovio Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get electroCore News Delivered to You Automatically Sign up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ECOR vs. The Competition Export to ExcelMetricelectroCoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.57M$2.84B$5.81B$10.17BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-2.9823.5174.6226.02Price / Sales1.45548.57466.0690.52Price / CashN/A169.2537.0859.91Price / Book4.275.3512.166.30Net Income-$11.89M$32.95M$3.29B$270.86M7 Day Performance-1.41%1.44%1.07%3.41%1 Month Performance7.61%8.70%7.38%6.56%1 Year Performance-17.59%0.55%63.13%28.27% electroCore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ECORelectroCore2.2309 of 5 stars$4.82-4.0%$25.50+428.9%-16.6%$36.57M$25.18M-2.9850INOInovio Pharmaceuticals3.6928 of 5 stars$2.87+2.9%$8.80+206.6%-59.5%$148.27M$220K-1.10320LNSRLENSAR1.6055 of 5 stars$12.34+1.4%$15.00+21.6%+145.1%$145.25M$53.49M-2.93110News CoveragePositive NewsLAKELakeland Industries4.8493 of 5 stars$15.00+0.1%$26.00+73.3%-27.2%$142.53M$177.65M-4.982,100News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionBSGMBiosig Technologies2.0558 of 5 stars$3.88-12.0%$10.00+157.7%+1,261.9%$138.56M$40K0.0050Gap DownPDEXPro-Dex2.7318 of 5 stars$35.57-6.9%$56.00+57.4%+36.9%$124.57M$66.59M13.17140Positive NewsHigh Trading VolumePROFProfound Medical2.063 of 5 stars$4.11-0.2%$11.00+167.6%-50.2%$123.82M$10.68M-2.82150Positive NewsRCELAvita Medical2.4564 of 5 stars$4.21-1.2%$11.60+175.5%-54.2%$113.40M$64.25M-2.14130SPAISafe Pro Group3.1029 of 5 stars$6.44-4.5%$8.00+24.2%+200.0%$108.97M$1.50M-8.0511Trending NewsAnalyst ForecastAnalyst RevisionOBIOOrchestra BioMed3.1171 of 5 stars$2.73-0.7%$13.50+394.5%-54.0%$106.27M$2.64M-1.494Short Interest ↑NSPRInspireMD3.6263 of 5 stars$2.40-0.8%$4.50+87.5%-9.7%$100.97M$7.07M-3.2050Short Interest ↓ Related Companies and Tools Related Companies INO Competitors LNSR Competitors LAKE Competitors BSGM Competitors PDEX Competitors PROF Competitors RCEL Competitors SPAI Competitors OBIO Competitors NSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ECOR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding electroCore, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share electroCore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ECOR Stock Alerts